DOI: https://doi.org/10.36347/sjams.2025.v13i02.037

Pages: 513-518

Background: Fifteen years have gone by since the approval of a topical treatment for atopic dermatitis (AD) with a novel mechanism of action, despite unmet demand. The effectiveness of topical Janus kinase (JAK) inhibitor therapy in AD patients is uncertain. Objectives: This study was done for assessment of efficacy of tofacitinib in atopic dermatitis such as vitiligo, atopic dermatitis, chronic dermatitis, prurigo nodularis lichen planus and prologis simplex. Methods: The cross-sectional Observational study was conducted in the Department of skin and VD, Ashiyan Medical College and Hospital from June 2022 to May 2023. A total of 82 patients of both sexes were included in the study. Data were collected over a period of 12 months and analyzed by appropriate computer based programmed software Statistical Package for the Social Sciences (SPSS), version 24. Results: In this study, about 31 (37.8%) patients lies between 31 years to 35 years and 22 (26.8%) patients lies between 36 years to 40 years. Mean ± SD of the patients age was 31.5 ± 7.3 years. More than half of the patients 48 (58.50%) were female and 34 (41.50%) patients were male. Most of the patients 52 (63.4%) BMI were in between normal range, 13 (15.9%) were underweight and 17 (20.7%) were overweight. Mean ± SD of the patients BMI was 29.3 ± 5.4 kg/m2. About 36 (43.9%) patients experienced severe itching, 35 (42.7%) patients experienced moderate itching and 11 (13.4%) patients experienced mild itching. Age of onset of the disease of most of the patients 48 (58.5%) were 10 – 12 years, 24 (29.3%) were 13 – 15 years and 10 (12.2%) were 16 – 18 years. Mean ± SD of the patients age of onset of disease was 12.0 ± 9.4 years. Conclusion: The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD.